Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. Cummings SR, et al. Among authors: krueger ka. JAMA. 1999 Jun 16;281(23):2189-97. doi: 10.1001/jama.281.23.2189. JAMA. 1999. PMID: 10376571 Clinical Trial.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Ettinger B, et al. JAMA. 1999 Aug 18;282(7):637-45. doi: 10.1001/jama.282.7.637. JAMA. 1999. PMID: 10517716 Clinical Trial.
Cognitive function in postmenopausal women treated with raloxifene.
Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T; Multiple Outcomes of Raloxifene Evaluation Investigators. Yaffe K, et al. N Engl J Med. 2001 Apr 19;344(16):1207-13. doi: 10.1056/NEJM200104193441604. N Engl J Med. 2001. PMID: 11309635 Free article. Clinical Trial.
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Cauley JA, et al. Among authors: krueger ka. Breast Cancer Res Treat. 2001 Jan;65(2):125-34. doi: 10.1023/a:1006478317173. Breast Cancer Res Treat. 2001. PMID: 11261828 Clinical Trial.
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW. Barrett-Connor E, et al. Among authors: krueger ka. Clin Ther. 2003 Mar;25(3):919-30. doi: 10.1016/s0149-2918(03)80114-5. Clin Ther. 2003. PMID: 12852708 Clinical Trial.
37 results